Veracyte (VCYT) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Veracyte (VCYT) to See Possible Medicare Payment Cut; Leerink Partners Cuts Price Target to $11
November 6, 2015 8:24 AM ESTLeerink Partners maintained an Outperform rating on Veracyte, Inc (NASDAQ: VCYT), and cut the price target to $11.00 (from $13.00), following the company's 3Q earnings report. VCYT reported Q3 revenue of $12.3M, slightly below the Streets $12.6M. VCYT noted some additional wins with Blues plans in the... More
